Kindred Biosciences Inc (NASDAQ:KIN) Director Raymond Townsend sold 6,419 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $9.45, for a total value of $60,659.55. Following the transaction, the director now directly owns 18,419 shares in the company, valued at approximately $174,059.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of Kindred Biosciences Inc (KIN) remained flat at $$9.15 during trading hours on Thursday. The company had a trading volume of 41,920 shares, compared to its average volume of 71,700. Kindred Biosciences Inc has a 1 year low of $5.00 and a 1 year high of $9.80. The company has a market cap of $254.72, a P/E ratio of -7.82 and a beta of 0.18.

Kindred Biosciences (NASDAQ:KIN) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. equities analysts predict that Kindred Biosciences Inc will post -1.19 earnings per share for the current year.

KIN has been the topic of a number of recent analyst reports. Zacks Investment Research downgraded Kindred Biosciences from a “buy” rating to a “hold” rating and set a $8.50 price target on the stock. in a research report on Tuesday, September 12th. HC Wainwright initiated coverage on Kindred Biosciences in a report on Friday, November 17th. They set a “buy” rating and a $9.50 price objective for the company. Aegis restated a “buy” rating on shares of Kindred Biosciences in a report on Friday, December 15th. ValuEngine cut Kindred Biosciences from a “hold” rating to a “sell” rating in a report on Wednesday. Finally, B. Riley restated a “buy” rating and set a $11.00 price objective on shares of Kindred Biosciences in a report on Monday, November 20th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $9.63.

Large investors have recently modified their holdings of the company. Nationwide Fund Advisors bought a new stake in shares of Kindred Biosciences during the second quarter worth approximately $100,000. JPMorgan Chase & Co. bought a new stake in shares of Kindred Biosciences in the second quarter valued at approximately $119,000. OxFORD Asset Management LLP bought a new stake in shares of Kindred Biosciences in the second quarter valued at approximately $128,000. State of Wisconsin Investment Board bought a new stake in shares of Kindred Biosciences in the second quarter valued at approximately $129,000. Finally, Virtu KCG Holdings LLC boosted its stake in shares of Kindred Biosciences by 41.7% in the second quarter. Virtu KCG Holdings LLC now owns 15,285 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 4,495 shares during the period. Institutional investors own 66.79% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2018/01/04/raymond-townsend-sells-6419-shares-of-kindred-biosciences-inc-kin-stock.html.

About Kindred Biosciences

Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.

Insider Buying and Selling by Quarter for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.